192 related articles for article (PubMed ID: 18322388)
1. Progress in the active immunotherapeutic approach to Alzheimer's disease: clinical investigations into AN1792-associated meningoencephalitis.
Pride M; Seubert P; Grundman M; Hagen M; Eldridge J; Black RS
Neurodegener Dis; 2008; 5(3-4):194-6. PubMed ID: 18322388
[TBL] [Abstract][Full Text] [Related]
2. Evaluation of the safety and immunogenicity of synthetic Abeta42 (AN1792) in patients with AD.
Bayer AJ; Bullock R; Jones RW; Wilkinson D; Paterson KR; Jenkins L; Millais SB; Donoghue S
Neurology; 2005 Jan; 64(1):94-101. PubMed ID: 15642910
[TBL] [Abstract][Full Text] [Related]
3. Immunotherapy as treatment for Alzheimer's disease.
Hawkes CA; McLaurin J
Expert Rev Neurother; 2007 Nov; 7(11):1535-48. PubMed ID: 17997702
[TBL] [Abstract][Full Text] [Related]
4. Amyloid-beta immunotherapy for Alzheimer's disease: the end of the beginning.
Schenk D
Nat Rev Neurosci; 2002 Oct; 3(10):824-8. PubMed ID: 12360327
[No Abstract] [Full Text] [Related]
5. Virus and virus-like particle-based immunogens for Alzheimer's disease induce antibody responses against amyloid-beta without concomitant T cell responses.
Chackerian B; Rangel M; Hunter Z; Peabody DS
Vaccine; 2006 Sep; 24(37-39):6321-31. PubMed ID: 16806604
[TBL] [Abstract][Full Text] [Related]
6. Intravenous immunoglobulin and Alzheimer's disease immunotherapy.
Solomon B
Curr Opin Mol Ther; 2007 Feb; 9(1):79-85. PubMed ID: 17330405
[TBL] [Abstract][Full Text] [Related]
7. Abeta42 immunization in Alzheimer's disease generates Abeta N-terminal antibodies.
Lee M; Bard F; Johnson-Wood K; Lee C; Hu K; Griffith SG; Black RS; Schenk D; Seubert P
Ann Neurol; 2005 Sep; 58(3):430-5. PubMed ID: 16130106
[TBL] [Abstract][Full Text] [Related]
8. Clinical effects of Abeta immunization (AN1792) in patients with AD in an interrupted trial.
Gilman S; Koller M; Black RS; Jenkins L; Griffith SG; Fox NC; Eisner L; Kirby L; Rovira MB; Forette F; Orgogozo JM;
Neurology; 2005 May; 64(9):1553-62. PubMed ID: 15883316
[TBL] [Abstract][Full Text] [Related]
9. [Abeta vaccine therapy for Alzheimer's disease].
Hara H
Rinsho Shinkeigaku; 2005 Nov; 45(11):867-9. PubMed ID: 16447748
[TBL] [Abstract][Full Text] [Related]
10. Immunization in Alzheimer's disease: naïve hope or realistic clinical potential?
Foster JK; Verdile G; Bates KA; Martins RN
Mol Psychiatry; 2009 Mar; 14(3):239-51. PubMed ID: 18957942
[TBL] [Abstract][Full Text] [Related]
11. Site-specific UBITh amyloid-beta vaccine for immunotherapy of Alzheimer's disease.
Wang CY; Finstad CL; Walfield AM; Sia C; Sokoll KK; Chang TY; Fang XD; Hung CH; Hutter-Paier B; Windisch M
Vaccine; 2007 Apr; 25(16):3041-52. PubMed ID: 17287052
[TBL] [Abstract][Full Text] [Related]
12. Vaccination of Alzheimer's model mice with adenovirus vector containing quadrivalent foldable Abeta(1-15) reduces Abeta burden and behavioral impairment without Abeta-specific T cell response.
Zou J; Yao Z; Zhang G; Wang H; Xu J; Yew DT; Forster EL
J Neurol Sci; 2008 Sep; 272(1-2):87-98. PubMed ID: 18571202
[TBL] [Abstract][Full Text] [Related]
13. [Novel vaccine therapy for Alzheimer's disease--recent progress and our approach].
Okura Y; Matsumoto Y
Brain Nerve; 2008 Aug; 60(8):931-40. PubMed ID: 18717197
[TBL] [Abstract][Full Text] [Related]
14. HLA-DR alleles in amyloid beta-peptide autoimmunity: a highly immunogenic role for the DRB1*1501 allele.
Zota V; Nemirovsky A; Baron R; Fisher Y; Selkoe DJ; Altmann DM; Weiner HL; Monsonego A
J Immunol; 2009 Sep; 183(5):3522-30. PubMed ID: 19675171
[TBL] [Abstract][Full Text] [Related]
15. [The lesions of Alzheimer's disease: which therapeutic perspectives?].
Duyckaerts C; Perruchini C; Lebouvier T; Potier MC
Bull Acad Natl Med; 2008 Feb; 192(2):303-18; discussion 318-21. PubMed ID: 18819685
[TBL] [Abstract][Full Text] [Related]
16. Development of anti-Abeta vaccination as a promising therapy for Alzheimer's disease.
Okura Y; Matsumoto Y
Drug News Perspect; 2007; 20(6):379-86. PubMed ID: 17925892
[TBL] [Abstract][Full Text] [Related]
17. Enhanced Th2 immunity after DNA prime-protein boost immunization with amyloid beta (1-42) plus CpG oligodeoxynucleotides in aged rats.
Subramanian S; Divya Shree AN
Neurosci Lett; 2008 May; 436(2):219-22. PubMed ID: 18394801
[TBL] [Abstract][Full Text] [Related]
18. Rationale for peptide and DNA based epitope vaccines for Alzheimer's disease immunotherapy.
Ghochikyan A
CNS Neurol Disord Drug Targets; 2009 Apr; 8(2):128-43. PubMed ID: 19355933
[TBL] [Abstract][Full Text] [Related]
19. Toxicity of beta-amyloid vaccination in patients with Alzheimer's disease.
Imbimbo BP
Ann Neurol; 2002 Jun; 51(6):794. PubMed ID: 12112091
[No Abstract] [Full Text] [Related]
20. Consequence of Abeta immunization on the vasculature of human Alzheimer's disease brain.
Boche D; Zotova E; Weller RO; Love S; Neal JW; Pickering RM; Wilkinson D; Holmes C; Nicoll JA
Brain; 2008 Dec; 131(Pt 12):3299-310. PubMed ID: 18953056
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
